A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki et al. · Journal of Thoracic Oncology · 2017
Cited by 179 works. doi:10.1016/j.jtho.2017.10.032 Open-access PDF
Authors
- Katsuyuki Hotta
- Keisuke Aoe
- Toshiyuki Kozuki
- Kadoaki Ohashi
- Kiichiro Ninomiya
- Eiki Ichihara
- Toshio Kubo
- Takashi Ninomiya
- Kenichi Chikamori
- Daijiro Harada
- Naoyuki Nogami
- Taizo Hirata
- Shiro Hinotsu
- Shinichi Toyooka
- Katsuyuki Kiura
References
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- HER2 YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
- Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
- Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy
- Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
- Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).